MicroRNA-23b is an independent prognostic marker and suppresses ovarian cancer progression by targeting runt-related transcription factor-2

FEBS Letters

Volumn 588, Issue 9, 2014, Pages 1608-1615

  Li, Weiping ^a   Liu, Zhongyu ^b   Chen, Li ^b   Zhou, Li ^c   Yao, Yuanqing ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b Postgraduate Medical School of PLA   (China)

^c The 477 Hospital of PLA   (China)

Author keywords

Clinicopathological feature; Epithelial ovarian cancer; MicroRNA 23b; Overall survival; Progression free survival; Runt related transcription factor 2

Indexed keywords

MICRORNA; MICRORNA 23B; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER PROGNOSIS; CARCINOGENICITY; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; MITOSIS INHIBITION; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CLINICOPATHOLOGICAL FEATURE; EPITHELIAL OVARIAN CANCER; MICRORNA-23B; OVERALL SURVIVAL; PROGRESSION-FREE SURVIVAL; RUNT-RELATED TRANSCRIPTION FACTOR-2;

CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CORE BINDING FACTOR ALPHA 1 SUBUNIT; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; KAPLAN-MEIER ESTIMATE; MICRORNAS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RNA INTERFERENCE;

EID: 84899647898     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1016/j.febslet.2014.02.055     Document Type: Article

References (30)

1. K. Kim, R. Zang, S.C. Choi, S.Y. Ryu, and J.W. Kim Current status of gynecological cancer in China J. Gynecol. Oncol. 20 2009 72 76
2. A.P.M. Heintz, F. Odicino, P. Maisonneuve, M.A. Quinn, J.L. Benedet, W.T. Creasman, H.Y.S. Ngan, S. Pecorelli, and U. Beller Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer Int. J. Gynecol. Obstet. 95 2006 S161 S192
3. S.J. Jordan, K.L. Cushing-Haugen, K.G. Wicklund, J.A. Doherty, and M.A. Rossing Breast-feeding and risk of epithelial ovarian cancer Cancer Causes Control 23 2012 919 927
4. M. Rota, E. Pasquali, L. Scotti, C. Pelucchi, I. Tramacere, F. Islami, E. Negri, P. Boffetta, R. Bellocco, G. Corrao, C. La Vecchia, and V. Bagnardi Alcohol drinking and epithelial ovarian cancer risk. A systematic review and meta-analysis Gynecol. Oncol. 125 2012 758 763
5. M. Wang, Y. He, L. Shi, and C. Shi Multivariate analysis by Cox proportional hazard model on prognosis of patient with epithelial ovarian cancer Eur. J. Gynaecol. Oncol. 32 2011 171 177
6. T.A. Farazi, J.I. Hoell, P. Morozov, and T. Tuschl MicroRNAs in human cancer Adv. Exp. Med. Biol. 774 2013 1 20
7. M.S. Zaman, D.M. Maher, S. Khan, M. Jaggi, and S.C. Chauhan Current status and implications of microRNAs in ovarian cancer diagnosis and therapy J. Ovarian Res. 5 2012 44
8. G. Di Leva, and C.M. Croce The role of microRNAs in the tumorigenesis of ovarian cancer Front. Oncol. 3 2013 153
9. H. Wu, Z. Xiao, K. Wang, W. Liu, and Q. Hao MiR-145 is downregulated in human ovarian cancer and modulates cell growth and invasion by targeting p70S6K1 and MUC1 Biochem. Biophys. Res. Commun. 441 2013 693 700
10. Y.Q. Wang, R.D. Guo, R.M. Guo, W. Sheng, and L.R. Yin MicroRNA-182 promotes cell growth, invasion, and chemoresistance by targeting programmed cell death 4 (PDCD4) in human ovarian carcinomas J. Cell Biochem. 114 2013 1464 1473
11. H. Zhang, Q. Wang, Q. Zhao, and W. Di MiR-124 inhibits the migration and invasion of ovarian cancer cells by targeting SphK1 J. Ovarian Res. 6 2013 84
12. N.O. Chimge, S.K. Baniwal, G.H. Little, Y.B. Chen, M. Kahn, D. Tripathy, Z. Borok, and B. Frenkel Regulation of breast cancer metastasis by RUNX2 and estrogen signaling: the role of SNAI2 Breast Cancer Res. 13 2011 R127
13. M.L. Slattery, A. Lundgreen, J.S. Herrick, B.J. Caan, J.D. Potter, and R.K. Wolff Associations between genetic variation in RUNX1, RUNX2, RUNX3, MAPK1 and eIF4E and risk of colon and rectal cancer: additional support for a TGF-β-signaling pathway Carcinogenesis 32 2011 318 326
14. W. Li, S. Xu, S. Lin, and W. Zhao Overexpression of runt-related transcription factor-2 is associated with advanced tumor progression and poor prognosis in epithelial ovarian cancer J. Biomed. Biotechnol. 2012 2012 456534
15. Z.Q. Wang, M. Keita, M. Bachvarova, S. Gobeil, C. Morin, M. Plante, J. Gregoire, M.C. Renaud, A. Sebastianelli, X.B. Trinh, and D. Bachvarov Inhibition of RUNX2 transcriptional activity blocks the proliferation, migration and invasion of epithelial ovarian carcinoma cells PLoS One 8 2013 e74384
16. H.C. He, J.G. Zhu, X.B. Chen, S.M. Chen, Z.D. Han, Q.S. Dai, X.H. Ling, X. Fu, Z.Y. Lin, Y.H. Deng, G.Q. Qin, C. Cai, J.H. Chen, and W.D. Zhong MicroRNA-23b downregulates peroxiredoxin III in human prostate cancer FEBS Lett. 586 2012 2451 2458
17. Y. Zhang, X. Guo, L. Xiong, X. Kong, Y. Xu, C. Liu, L. Zou, Z. Li, J. Zhao, and N. Lin MicroRNA-101 suppresses SOX9-dependent tumorigenicity and promotes favorable prognosis of human hepatocellular carcinoma FEBS Lett. 586 2012 4362 4370
18. Y.T. Park, J.Y. Jeong, M.J. Lee, K.I. Kim, T.H. Kim, Y.D. Kwon, C. Lee, O.J. Kim, and H.J. An MicroRNAs overexpressed in ovarian ALDH1-positive cells are associated with chemoresistance J. Ovarian Res. 6 2013 18
19. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics CA Cancer J. Clin. 63 2013 11 30
20. M. Fung-Kee-Fung, T. Oliver, L. Elit, A. Oza, H.W. Hirte, and P. Bryson Optimal chemotherapy treatment for women with recurrent ovarian cancer Curr. Oncol. 14 2007 195 208
21. L. Jin, O. Wessely, E.G. Marcusson, C. Ivan, G.A. Calin, and S.K. Alahari Prooncogenic factors miR-23b and miR-27b are regulated by Her2/Neu, EGF, and TNF-α in breast cancer Cancer Res. 73 2013 2884 2896
22. M.S. Zaman, S. Thamminana, V. Shahryari, T. Chiyomaru, G. Deng, S. Saini, S. Majid, S. Fukuhara, I. Chang, S. Arora, H. Hirata, K. Ueno, K. Singh, Y. Tanaka, and R. Dahiya Inhibition of PTEN gene expression by oncogenic miR-23b-3p in renal cancer PLoS One 7 2012 e50203
23. S. Majid, A.A. Dar, S. Saini, G. Deng, I. Chang, K. Greene, Y. Tanaka, R. Dahiya, and S. Yamamura MicroRNA-23b functions as a tumor suppressor by regulating Zeb1 in bladder cancer PLoS One 8 2013 e67686
24. R.A. Ishteiwy, T.M. Ward, D.M. Dykxhoorn, and K.L. Burnstein The microRNA-23b/-27b cluster suppresses the metastatic phenotype of castration-resistant prostate cancer cells PLoS One 7 2012 e52106
25. A. Salvi, C. Sabelli, S. Moncini, M. Venturin, B. Arici, P. Riva, N. Portolani, S.M. Giulini, G. De Petro, and S. Barlati MicroRNA-23b mediates urokinase and c-met downmodulation and a decreased migration of human hepatocellular carcinoma cells FEBS J. 276 2009 2966 2982
26. C. Sperling, M.C. Noer, I.J. Christensen, M.L. Nielsen, ∅. Lidegaard, and C. Høgdall Comorbidity is an independent prognostic factor for the survival of ovarian cancer: a Danish register-based cohort study from a clinical database Gynecol. Oncol. 129 2013 97 102
27. N. Linder, R. Bützow, H. Lassus, M. Lundin, and J. Lundin Decreased xanthine oxidoreductase (XOR) is associated with a worse prognosis in patients with serous ovarian carcinoma Gynecol. Oncol. 124 2012 311 318
28. H. Zheng, Y.N. Gao, W.J. Gao, M. Gao, and X. Yan Expression of serum human epididymis protein 4 in epithelial ovarian cancer and its correlation with prognosis Zhonghua Zhong Liu Za Zhi 35 2013 445 449
29. D. Jelovac, and D.K. Armstrong Recent progress in the diagnosis and treatment of ovarian cancer CA Cancer J. Clin. 61 2011 183 203
30. W.E. Winter 3rd, G.L. Maxwell, C. Tian, J.W. Carlson, R.F. Ozols, P.G. Rose, M. Markman, D.K. Armstrong, F. Muggia, W.P. McGuire Gynecologic Oncology Group Study Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study J. Clin. Oncol. 25 2007 3621 3627